Psychiatrist develops AI platform to precisely evaluate severe depression

Early in his career, Dr. Cheng-Ta Li went looking for advice about magnetic brain stimulation and was told by a senior psychiatrist that the research had probably already reached its limits. He tried it anyway. Today Dr. Li, who directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital and holds an appointment at the School of Medicine of National Yang Ming Chiao Tung University, wants psychiatry to stop treating "treatment-resistant depression" as a simple yes-or-no label. Resistance, in his view, is not a wall. It is a road, and patients stand at different points along it.

Opened in June 2022 as the first center in Taiwan devoted specifically to the precision assessment and treatment of depression, PreDIC has provided clinical services to more than 20,000 treatment-resistant depression (TRD) patient visits. Its signature tool, AI-PreDIC®, is a patented platform combining clinical information with biological measurements, including EEG and FDG-PET brain imaging, to give objective estimates of how severe a depression is and how stubbornly it has refused to yield. Consider the difference between a forecast that says only "storm" and one that reports wind speed, pressure, and the track of the eye.

"The key question in TRD is not simply whether a treatment works on average, but which treatment is most likely to help a particular patient at a particular stage of illness," Dr. Li says.

The field he almost refused

Dr. Li was born in Taichung. As a medical student he wanted to know how everything worked: not only the brain but muscles, tendons, the whole humming machinery of the body. Psychiatry claimed him during clinical rotations, largely because so much of it remained unexplained. Then came the patients he could not forget, people with severe depression who had spent one or even two years in psychotherapy and conventional treatment, surrounded by families and clinicians who were doing everything right, and who still were not getting well.

When a mentor nudged him toward repetitive transcranial magnetic stimulation (rTMS), he hesitated, and the senior psychiatrist he consulted only deepened the doubt. He went ahead regardless. Some patients who had stayed depressed through prolonged treatment improved within a relatively short time, and what struck him most was not the lifting of mood but the way they began to see themselves, their circumstances, and their future. "Ironically, the field I was initially most reluctant to enter eventually became one of the defining themes of my career," he says.

He trained in functional neuroimaging, earned a PhD at the Institute of Brain Science under Professor Jen-Chuen Hsieh and Professor Tung-Ping Su, and completed a fellowship in the Molecular Imaging Branch of the U.S. National Institute of Mental Health with Professor Robert Innis. Back home he worked on brain stimulation and low-dose ketamine when both were still unfamiliar in clinical psychiatric settings. His 2014 study in the journal Brain was among the first large randomized sham-controlled trials of theta-burst stimulation for refractory depression, and he joined the effort to bring rTMS toward regulatory approval for depression in Taiwan. That slog taught him that evidence does not walk into a clinic by itself. It needs infrastructure, education, regulatory conversation, and people from different disciplines willing to share a table. That conviction lies behind both PreDIC and the Taiwanese Society of Brain Stimulation, of which he is founding President; the society held its first annual meeting in August 2026. He has also served as Secretary General of the Asian College of Neuropsychopharmacology and currently serves as a Councilor of the International College of Neuropsychopharmacology (CINP).

Treatment resistance as a continuum

His current work treats refractoriness as a continuum and asks how longitudinal biological adaptation might push a patient further along it. His group uses EEG, MRI, PET, and artificial intelligence to characterize depression, and population studies he coauthored have shown that TRD runs in families: in a 2024 JAMA Psychiatry analysis of national health insurance data for all of Taiwan, first-degree relatives of people with TRD were 9.16 times more likely to receive the diagnosis themselves. With more than 300 peer-reviewed publications to his name, Dr. Li has carried the science into patents, technology transfer, clinical consensus development, and professional training. He is also developing new treatments for difficult-to-treat mood disorders, from brain stimulation to emerging approaches such as psychedelics, and he wants the knowledge to leave the hospital through AI-based mental health chatbots, books, public lectures, and social media.

He is unsentimental about evidence. Findings, he argues, should be judged by how strong their evidence is, not by whether they were published or where they come from; exploratory studies and negative results matter, provided their limits are stated plainly. Asked to name his greatest fear, he gives an answer that doubles as a warning to his field: "Seeing patients place their trust in ineffective or unproven treatments and, as a result, miss the opportunity to receive appropriate care."

Curiosity, evidence, and Michael Faraday

Asked about regrets, Dr. Li names one that is personal. "I wish I had understood more about mental health when my grandmother was still alive," he says. It is a reminder that distress can surface as physical complaints that are easy to overlook.

He is proud that financial gain has never been a major motivation in his career. Among his most treasured possessions are a government award plaque for scientific excellence and his family photographs. He plays badminton, hikes and travels with his family, admits a weakness for new electronic gadgets, and considers busyness for its own sake the most overrated virtue, because real progress usually needs time to reflect.

Given dinner with any historical figure, he would choose Michael Faraday, to ask how someone with very little formal education made so many discoveries in physics and chemistry. It is a fitting choice for a man once told his chosen field had nothing left to give, who decided to find out for himself. His motto is short: "Stay curious, question what you believe, and persist in what truly matters."

Source:
Journal reference:

Cheng-Ta Li., (2026) Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression. Brain Medicine. https://doi.org/10.61373/bm026k.0066

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CHLA researcher explores immune mechanisms behind rare pediatric neuroinflammatory diseases